Home ›
Kidney Cancer Trials ›
NCT07872553
A Study of Treatment Delivery Preference In People With Kidney Cancer
The purpose of this study is to see if people prefer immunotherapy treatment for kidney cancer delivered intravenously or subcutaneously and if it is practical for participants to receive labs at home and have a video (telehealth) visit with their doctor prior to their day of treatment.
Trial Details
NCT ID NCT07872553
Phase PHASE4
Sponsor Memorial Sloan Kettering Cancer Center
Status RECRUITING
Cancer Type Kidney Cancer
Interventions Nivolumab Injectable Product Nivolumab Pembrolizumab injection Pembrolizumab
Locations (sample) Basking Ridge, New Jersey, United States|40.70621,-74.54932 Middletown, New Jersey, United States|40.39428,-74.11709 Montvale, New Jersey, United States|41.04676,-74.02292 Commack, New York, United States|40.84288,-73.29289 Harrison, New York, United States|40.96899,-73.71263
Key Eligibility Criteria
A patient cannot be considered eligible for this study unless ALL of the following conditions are met. Patient is receiving standard of care treatment for renal cell carcinoma for one of the following indications: 1) NIVO monotherapy as maintenance, … For patients on NIVO monotherapy or PEMBRO (Groups 2 and 3 above), they must have received at least 1 dose as a standard of care to be eligible Patient has at least 6 doses of planned treatment left as standard of care that can be given on protocol (either NIVO or PEMBRO)
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Kidney Cancer Trials on Trialify →